SGLT-2i use before COVID-19 may reduce adverse outcomes in diabetes patients
For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-related adverse outcomes, ...
Dec 7, 2022
0
9